At A Glance:

This sponsor had blockbuster expectations for its compound in the treatment of moderate-to-severe atopic dermatitis when it began its Phase III study.

Download PDF
Indication:

Atopic Dermatitis


Randomized patients delivered: 25%
Enrollment cost saved: $2.2 million
See the results